Optimizing therapeutic antibody function: Progress with fc domain engineering

BioDrugs

Volumn 25, Issue 1, 2011, Pages 1-11

  Kaneko, Etsuji ^a   Niwa, Rinpei ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antibodies, general; Immunoglobulin Fc fragments, general; Research and development

Indexed keywords

AME 133; ANTIBODY; CD16 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; NATALIZUMAB; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; GENE MUTATION; HUMAN; IMMUNOGENICITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MUTATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, FC;

EID: 78651360674     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11537830-000000000-00000     Document Type: Review

References (96)

1. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region do-mains. Proc Natl Acad Sci USA 1984; 81: 6851-5
2. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity- determining regionsinahuman antibody withthosefromamouse. Nature 1986; 321: 522-5
3. Winter G, Griffiths AD, Hawkins RE, et al. Making antibodies by phage display technology. Annu Rev Immunol 1994; (12): 433-55
4. Huls GA, Heijnen IA, Cuomo ME, et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 1999; 17: 276-81
5. Tomizuka K, Yoshida H, Uejima H, et al. Functional expression and germline atransmission of a human chromosome fragment in chimaeric mice. Nat Genet 1997; 16: 133-43
6. Mendez MJ, Green LL, Corvalan JR, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15: 146-56
7. Rothlisbergera D, Honeggera A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347: 773-89
8. Presta LG, Shields RL, Namenuk AK, et al. Engineering therapeutic antibodies for improved function. Biochem Soc Trans 2002; 30: 487-90
9. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-ANG resolution. Biochemistry 1981; 20: 2361-70
10. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372: 379-83
11. Koene H R, Kleijer M, Algra J, et al. FcRIIIa-158V/ Fpolymorphisminfluences the binding of Ig G by natural killer Cell FcRIIIa, independently of the FcRIIIa-48L/R/H phenotype. Blood 1997; 90 (3): 1109-14
12. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in Ig G Fc receptor FcRIIIa gene. Blood 2002; 99: 754-8
13. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-7
14. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-9
15. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96
16. Bibeau F, Lopez-Crapez E, Fiore FD, et al. Impact of FcRIIa-FcRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-9
17. Miescher S, Spycher MO, Amstutz H, et al. A single recombinant anti-Rh D Ig G prevents Rh D immunization: association of Rh D-positive red blood cell clearance rate with polymorphisms in the FcγRIIA and FcγIIIA genes. Blood 2004; 103: 4028-35
18. Salmon JE, Edberg JC, Brogle NL, et al. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB: independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274-81
19. Lejeune J, Thibault G, Ternant D, et al. Evidence for linkage disequilibrium between FcRIIIa-V158F and FcRIIa-H131R polymorphisms in white pa-tients, and for an FcRIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26: 5489-91
20. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-8
21. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell ma-lignancies. J Immunother 2001; 24: 263-71
22. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111: 1094-100
23. Roopenian D C, Shreeram A. Fc Rn: theneonatalFcreceptorcomesofage. Nat Rev Immunol 2007; 7: 715-25
24. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like Ig G receptor controls perinatal Ig G transport, Ig G homeostasis, and fate of Ig G-Fc-coupled drugs. J Immunol 2003; 170: 3528-33
25. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on Human Ig G1 for FcγRI, FcγRII, FcγRIII, and Fc Rn and design ofIg G1 variants with improved binding to the FcγR. J Biol Chem 2001; 276: 6591-604
26. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-10
27. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res 2007; 67: 8882-90
28. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571-5
29. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human Ig G1 antibody with longer serum half-life. J Immunol 2006; 176: 346-56
30. Dall'Acqua WF, Kiener PA, Wu H. Properties of human Ig G1s engineered for enhanced binding to the neonatal Fc receptor (Fc Rn). J Biol Chem 2006; 281 (33): 23514-24
31. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28: 157-9
32. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6
33. Richards JO, Karki S, Lazar GA, et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7: 2517-27
34. Hodoniczky J, Zheng YZ, James DC Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21: 1644-52
35. Scallon BJ, Tam SH, Mc Carthy SG, et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-34
36. Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma Ig G1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17: 176-80
37. Schuster M, Umana P, Ferrara C, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 2005; 65: 7934-41
38. Shields RL, Lai J, Keck R, et al. Lack of fucose on human Ig G1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-40
39. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose butnot the presence of galactose or bisecting N-acetylglucosamine of human Ig G1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73
40. Matsumiya S, Yamaguchi Y, Saito J, et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007; 368: 767-79
41. Ferrara C, Stuart F, Sondermann P, et al. The carbohydrate at FcγRIIIa Asn-162: an element required for high affinity binding to nonfucosylated Ig G glycoforms. J Biol Chem 2006; 281: 5032-6
42. Shibata-Koyama M, Iida S, Okazaki A, et al. The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to Ig G glycoforms lacking core fucosylation. Glycobiology 2009; 19: 126-34
43. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 Ig G1 with enhanced antibody-dependent cellular cyto-toxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33
44. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose Ig G1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11: 2327-36
45. Niwa R, Hatanaka S, Shoji-Hosaka E, et al. Enhancement of the antibodydependent cellular cytotoxicity of low-fucose Ig G1 is independent of FcγRIIIa functional polymorphism. Clin Cancer Res 2004; 10: 6248-55
46. Harada H, Kamei M, Tokumoto Y, et al. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 1987; 164: 374-81
47. Mizuochi T, Taniguchi T, Shimizu A, et al. Structural and numerical variations of the. carbohydrate moiety of immunoglobulin G. J Immunol 1982; 129: 2016-20
48. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic Ig G1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res 2006; 12: 2879-87
49. Miyoshi E, Noda K, Yamaguchi Y, et al. The α-1-6-fucosyltransferase gene and its biological significance. Biochem Biophys Acta 1999; 1473: 9-20
50. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for produc-ing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87: 614-22
51. Kanda Y, Yamane-Ohnuki N, Sakai N, et al. Comparison ofcell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 2006; 94: 680-8
52. Li H, Sethuraman N, Stadheim TA, et al. Optimization of humanized Ig Gs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24: 210-5
53. Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24: 1591-7
54. Schuster M, Jost W, Mudde GC, et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007; 2: 700-8
55. Choi BK, Bobrowicz P, Davidson RC, et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci USA 2003; 100: 5022-7
56. Bobrowicz P, Davidson RC, Li H, et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 2004; 14: 757-66
57. Hamilton SR, Davidson RC, Sethuraman N, et al. Humanization of yeast to producecomplexterminally sialylatedglycoproteins. Science 2006; 313:1441-3
58. Shopes B. Agenetically engineeredhumanIg Gmutant withenhancedcytolytic activity. J Immunol 1992; 148 (9): 2918-22
59. Azuma Y, Ishikawa Y, Kawai S, et al. Recombinant human hexamer-dominant Ig M monoclonal antibody to ganglioside GM3 for treatment of mela-noma. Clin Cancer Res 2007; 13: 2745-50
60. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human Ig G1 Fc. J Immunol 2000; 164: 4178-84
61. Natsume A, In M, Takamura H, et al. Engineered antibodies of Ig G1/Ig G3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 3863-72
62. Natsume A, Shimizu-Yokoyama Y, Satoh M, et al. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci 2009; 100: 2411-8
63. Zuckier LS, Chang CJ, Scharff MD, et al. Chimeric human-mouse Ig G antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res 1998; 58: 3905-8
64. Yeung YA, Leabman MK, Marvin JS, et al. Engineering human Ig G1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharma-cokinetics in primates. J Immunol 2009; 182: 7663-71
65. Bergman I, Basse PH, Barmada MA, et al. Comparison of in vitro antibodytargeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000; 49: 259-66
66. Nimmerjahn F, Bruhns P, Horiuchi K, et al. FcRIV: a novel Fc R with distinct Ig G subclass specificity. Immunity 2005; 23: 41-51
67. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-2
68. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45
69. Zalevsky J, Leung IW, Karki S, et al. The impact of Fc engineering on an antiCD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009; 113: 3735-43
70. Garcia-Iglesias T, del Toro-Arreola A, Albarran-Somoza B, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009; 9: 186
71. Lee J C, Lee K M, Kim D W, et al. ElevatedTGF-1 secretionanddown- modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40
72. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leuke-mia. Blood 2002; 99: 3661-67
73. Kono K, Takahashi A, Ichihara F, et al. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002; 62: 5813-7
74. Kuss I, Saito T, Johnson JT, et al. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999; 5: 329-34
75. Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human Ig G1 oligosaccharide enhances binding enthalpy and association rate be-tween Ig G1 and FcγRIIIa. J Mol Biol 2004; 336: 1239-49
76. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20: 685-91
77. Niwa R, Natsume A, Uehara A, et al. Ig G subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306: 151-60
78. Natsume A, Wakitani M, Yamane-Ohnuki N, et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain anti-body linked the antibody constant region. J Immunol Methods 2005; 306: 93-103
79. Shoji-Hosaka E, Kobayashi Y, Wakitani M, et al. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 2006; 140: 777-83
80. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs 2005; 65: 2405-27
81. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356: 2622-9
82. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive proper-ties. Eur J Immunol 1993; 23: 403-11
83. Alegre ML, Peterson LJ, Xu D, et al. Anon-activating " humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Trans-plantation 1994; 57: 1537-43
84. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OTK3 effector function variant antibody. Cell Immunol 2000; 100: 16-26
85. An Z, Forrest G, Moore R, et al. Ig G2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1: 572-9
86. Ridgway JB1, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617-21
87. Merchant AM, Zhu Z, Yuan JQ, et al. An efficient route to human bispecific Ig G. Nat Biotechnol 1998; 1: 677-81
88. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 2007; 178: 4169-76
89. Lunde E, Lauvrak V, Rasmussen IB, et al. Troybodiesandpepbodies. Biochem Soc Trans 2002; 30: 500-6
90. Tunheim G, Schjetne KW, Fredriksen AB, et al. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes. J Leukoc Biol 2005; 77: 303-10
91. Wozniak-Knopp G, Bartl S, Bauer A, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010 Apr; 23 (4): 289-97
92. Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005; 28: 212-9
93. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108: 2648-54
94. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy ofCD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. Epub 2010 Mar 1
95. Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007; 7: 405-18
96. Stas P, Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 2009; 12: 169-73